Clinical Trial: NCT04993690
A Study of LP-168 in Participants With Relapse or Refractory B-Cell Lymphoma
Status:
RECRUITINGPhase:
Phase 1| Lead Sponsor: | Guangzhou Lupeng Pharmaceutical Company LTD. |
| Information Provided By: | Guangzhou Lupeng Pharmaceutical Company LTD. |
| Last Update Posted: | 2026-09-14 |
Study Overview
Brief Summary
This is an open-label, multi-center Phase 1/2 study of oral LP-168 in patients with CLL/SLL and NHL who have failed or are intolerant to standard of care.
Official Title
A Phase 1 Open-Label Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of LP-168 in Adult Patients With Relapse or Refractory B-Cell Lymphoma
Conditions
B-cell Lymphoma
Intervention / Treatment
- Drug: LP-168 tablet
Other Study ID Numbers
- LP-168-CN101
Start Date (Actual)
2021-07-06
Primary Completion Date (Estimated)
2027-03-31
Study Completion Date (Estimated)
2027-09-30
Enrollment (Estimated)
200
Study Type
Interventional
Phase
Phase 1
| Lead Sponsor: | Guangzhou Lupeng Pharmaceutical Company LTD. |
| Information Provided By: | Guangzhou Lupeng Pharmaceutical Company LTD. |
| Last Update Posted: | 2026-09-14 |
Study Overview
Brief Summary
This is an open-label, multi-center Phase 1/2 study of oral LP-168 in patients with CLL/SLL and NHL who have failed or are intolerant to standard of care.
Official Title
A Phase 1 Open-Label Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of LP-168 in Adult Patients With Relapse or Refractory B-Cell Lymphoma
Conditions
B-cell Lymphoma
Intervention / Treatment
- Drug: LP-168 tablet
Other Study ID Numbers
- LP-168-CN101
Start Date (Actual)
2021-07-06
Primary Completion Date (Estimated)
2027-03-31
Study Completion Date (Estimated)
2027-09-30
Enrollment (Estimated)
200
Study Type
Interventional
Phase
Phase 1